Considering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the Details

Pacira Biosciences Inc (NASDAQ:PCRX) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. Analysts expect the stock to pop more than 20% from its current level.

Considering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the Details

Pacira Biosciences Inc (NASDAQ:PCRX) reported its Q1 2026 results on April 30. It said revenue jumped 5% YoY to $177.4 million and surpassed the projected $172.46 million. The company recorded growth across its commercial portfolio, including a 7% increase in Exparel sales volume. Exparel is the company’s flagship product, and it contributed more than 80% of the company’s total revenue.

Pacira Biosciences delivered a GAAP net income of $2.9 million, compared with $4.8 million in the prior year as it faced higher expenses in areas like research programs. The company wrapped up the quarter with $202.2 million in cash. It spent $50 million on share buybacks during the quarter.

Looking ahead, Pacira Biosciences expects full-year 2026 total revenue in the range of $745 million to $770 million. Exparel sales are projected in the band of $600 million to $620 million.

As it works to grow sales with its existing commercial portfolio, Pacira Biosciences is also advancing its various pipeline projects. The company expects topline data from the Phase 2 ASCEND study of its PCRX-201 program by the end of 2026. PCRX-201 is a gene therapy for treating knee osteoarthritis, a condition that affects some 15 million Americans.

Pacira Biosciences Inc (NASDAQ:PCRX) develops non-opioid pain management solutions. The company has several commercial products along with several pipeline projects. The company’s solutions are designed to address unmet medical needs in the targeted fields.

While we acknowledge the risk and potential of PCRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PCRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Best Small Cap Agriculture Stocks to Buy Now and 8 Best Gold Stocks Under $5.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1